HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
Hims & Hers Health (HIMS) experienced a 7.36% increase in its stock price to $30.13 on Friday, after a 5.3% drop on Thursday. This surge was sparked by a Washington Post report that the Trump administration is planning to temporarily allow the sale of certain restricted peptides. The development aligns with HIMS' growth strategy, which includes launching sermorelin, glutathione, NAD+, and BPC-157 products by the end of 2026.
A National Association of Boards of Pharmacy report highlights the growing demand for peptides, potentially outweighing GLP-1s. Truist Securities maintained a Hold rating with a $32 price target on HIMS on Thursday, contributing to the day's decline. The current consensus among 16 brokerages is a Hold rating with an average 12-month target price of $32.50, with one sell rating suggesting a potential 17% downside.
HIMS' commitment to offering peptides by year-end 2026, coupled with its existing telehealth infrastructure, positions it as the most ready publicly traded platform to capitalize on expanded compounding-pharmacy peptide access. The next key event for HIMS will be its Q3 2026 earnings report on November 9, 2026, which will assess the gross margin mix following its peptide launch.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
